Andrew Kung

Andrew Kung serves as the Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center since July 2016. Additionally, Andrew is a Co-Founder and Board member of Isabl and holds positions on the Scientific Advisory Boards of multiple companies including Karyopharm Therapeutics Inc., Emendo Biotherapeutics, and DarwinHealth. Prior experience includes leadership roles at Columbia University Irving Medical Center and Dana-Farber Cancer Institute, where Andrew contributed to pediatric hematology/oncology and held various academic positions. Education includes a Doctor of Philosophy in Cancer Biology and a Doctor of Medicine from Stanford University School of Medicine, as well as a Bachelor of Science in Biochemistry from Florida State University.